These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 7555211)

  • 1. Does P-glycoprotein play a pivotal role in the drug resistance of an MDR variant, K562/Dox?
    Hu X; Yang H; Pan QR; Zheng S
    Chemotherapy; 1995; 41(4):296-305. PubMed ID: 7555211
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Reduced intracellular drug accumulation related to overexpression of P-glycoprotein cannot explain the complete drug resistance in MDR cell variant K562/Dox].
    Hu X; Pan Q; Zheng S
    Zhonghua Zhong Liu Za Zhi; 1995 Mar; 17(2):85-8. PubMed ID: 7656812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multidrug resistance in leukemic cell line K562/A02 induced by doxorubicin.
    Yang CZ; Luan FJ; Xiong DS; Liu BR; Xu YF; Gu KS
    Zhongguo Yao Li Xue Bao; 1995 Jul; 16(4):333-7. PubMed ID: 7668104
    [TBL] [Abstract][Full Text] [Related]  

  • 4. C-phycocyanin to overcome the multidrug resistance phenotype in human erythroleukemias with or without interaction with ABC transporters.
    Fernandes E Silva E; Figueira FS; Cañedo AD; Machado KS; Salgado MTSF; Silva TK; Wagner EF; Mattozo FH; Lima ÉA; Sales-Neto JM; Ferreira VU; Comitre AA; Mascarenhas SR; Kalil SJ; Votto APS
    Biomed Pharmacother; 2018 Oct; 106():532-542. PubMed ID: 29990841
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restoration of intracellular drug accumulation in MDR cell line K562r does not mean reversal of its drug resistance.
    Hu X; Chen WY
    Zhongguo Yao Li Xue Bao; 1994 Sep; 15(5):422-6. PubMed ID: 7717067
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overexpression of the multidrug resistance-associated protein (MRP) gene in vincristine but not doxorubicin-selected multidrug-resistant murine erythroleukemia cells.
    Slapak CA; Fracasso PM; Martell RL; Toppmeyer DL; Lecerf JM; Levy SB
    Cancer Res; 1994 Nov; 54(21):5607-13. PubMed ID: 7923205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
    Jiang XR; Kelsey SM; Wu YL; Newland AC
    Br J Haematol; 1995 Jun; 90(2):375-83. PubMed ID: 7794760
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reversal of P-glycoprotein-mediated multidrug resistance by guggulsterone in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Xu HB; Li L; Liu GQ
    Pharmazie; 2009 Oct; 64(10):660-5. PubMed ID: 19947169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reversal of p-glycoprotein-mediated multidrug resistance by CJX1, an amlodipine derivative, in doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Ji BS; He L; Liu GQ
    Life Sci; 2005 Sep; 77(18):2221-32. PubMed ID: 15967469
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of mechanisms responsible for resistance to idarubicin and daunorubicin in multidrug resistant LoVo cell lines.
    Toffoli G; Simone F; Gigante M; Boiocchi M
    Biochem Pharmacol; 1994 Nov; 48(10):1871-81. PubMed ID: 7986198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential effects of peroxisome proliferator-activated receptor agonists on doxorubicin-resistant human myelogenous leukemia (K562/DOX) cells.
    Yousefi B; Samadi N; Baradaran B; Rameshknia V; Shafiei-Irannejad V; Majidinia M; Targhaze N; Zarghami N
    Cell Mol Biol (Noisy-le-grand); 2015 Dec; 61(8):118-22. PubMed ID: 26718439
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
    Misra R; Sahoo SK
    Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lack of elevated drug efflux in adriamycin-resistant immunoblastic B lymphoma cells with mdr1 overexpression.
    Chao CC
    FEBS Lett; 1995 Oct; 373(3):285-90. PubMed ID: 7589484
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation among the resistance factor, kinetics of uptake, and kinetics of the P-glycoprotein-mediated efflux of doxorubicin, daunorubicin, 8-(S)-fluoroidarubicin, and idarubicin in multidrug-resistant K562 cells.
    Mankhetkorn S; Dubru F; Hesschenbrouck J; Fiallo M; Garnier-Suillerot A
    Mol Pharmacol; 1996 Mar; 49(3):532-9. PubMed ID: 8643093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Reversal effect of haloperidol on doxorubicin resistance and chloride channel inhibition in erythroleukemic cell K562/Dox].
    Zhou JH; Wu DZ
    Zhonghua Zhong Liu Za Zhi; 2005 Feb; 27(2):81-5. PubMed ID: 15946544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reversal of P-glycoprotein mediated multidrug resistance in K562 cell line by a novel synthetic calmodulin inhibitor, E6.
    Zhu HJ; Wang JS; Guo QL; Jiang Y; Liu GQ
    Biol Pharm Bull; 2005 Oct; 28(10):1974-8. PubMed ID: 16204958
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of multidrug resistance with antisense oligodeoxynucleotide to mdr1 mRNA.
    Sola JE; Colombani PM
    Ann Surg Oncol; 1996 Jan; 3(1):80-5. PubMed ID: 8770307
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P-glycoprotein-mediated efflux of hydroxyrubicin, a neutral anthracycline derivative, in resistant K562 cells.
    Borrel MN; Fiallo M; Priebe W; Garnier-Suillerot A
    FEBS Lett; 1994 Dec; 356(2-3):287-99. PubMed ID: 7805856
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HOXB4 knockdown reverses multidrug resistance of human myelogenous leukemia K562/ADM cells by downregulating P-gp, MRP1 and BCRP expression via PI3K/Akt signaling pathway.
    Wang H; Jia XH; Chen JR; Yi YJ; Wang JY; Li YJ; Xie SY
    Int J Oncol; 2016 Dec; 49(6):2529-2537. PubMed ID: 27779650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting P-glycoprotein expression and cancer cell energy metabolism: combination of metformin and 2-deoxyglucose reverses the multidrug resistance of K562/Dox cells to doxorubicin.
    Xue C; Wang C; Liu Q; Meng Q; Sun H; Huo X; Ma X; Liu Z; Ma X; Peng J; Liu K
    Tumour Biol; 2016 Jul; 37(7):8587-97. PubMed ID: 26733176
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.